Journal article
Effect of fenofibrate on uric acid and gout in type 2 diabetes: a post-hoc analysis of the randomised, controlled FIELD study
B Waldman, JC Ansquer, DR Sullivan, AJ Jenkins, N McGill, L Buizen, TME Davis, JD Best, L Li, MD Feher, C Foucher, YA Kesaniemi, J Flack, MC d'Emden, RS Scott, J Hedley, V Gebski, AC Keech
Lancet Diabetes and Endocrinology | ELSEVIER SCIENCE INC | Published : 2018
Abstract
Background: Gout is a painful disorder and is common in type 2 diabetes. Fenofibrate lowers uric acid and reduces gout attacks in small, short-term studies. Whether fenofibrate produces sustained reductions in uric acid and gout attacks is unknown. Methods: In the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) trial, participants aged 50–75 years with type 2 diabetes were randomly assigned to receive either co-micronised fenofibrate 200 mg once per day or matching placebo for a median of 5 years follow-up. We did a post-hoc analysis of recorded on-study gout attacks and plasma uric acid concentrations according to treatment allocation. The outcomes of this analysis were chan..
View full abstractGrants
Awarded by Abbott Laboratories
Funding Acknowledgements
This secondary analysis of the FIELD study had no specific funding, but was supported by an National Health and Medical Research Council (NHMRC) programme grant (1037786) to the NHMRC Clinical Trials Centre. The original FIELD study was supported by grants from Laboratoires Fournier SA, Dijon, France (subsequently part of Solvay Pharmaceuticals, then Abbott Laboratories, now Mylan) and the National Health and Medical Research Council (NHMRC) of Australia, and was coordinated independently by the NHMRC Clinical Trials Centre, University of Sydney, Sydney, Australia, under the direction of the academic FIELD steering committee. The FIELD investigators thank the Heart Foundation Australia, Diabetes Australia, Diabetes New Zealand and the Finnish Diabetes Association for endorsing the FIELD study. We would like to acknowledge the help of Rachel O'Connell with regards to statical validation of the results.